Loading...

APC anti-human CD69 Antibody

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50_APC_042706
PMA+ionomycin-stimulated (5hours) human peripheral blood lymphocytes stained with FN50 APC
  • FN50_APC_042706
    PMA+ionomycin-stimulated (5hours) human peripheral blood lymphocytes stained with FN50 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
310909 25 tests 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310910 100 tests 124€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  2. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  3. Rosato F, et al. 2022. J Transl Med. 20:578. PubMed
  4. Mamula D, et al. 2022. NPJ Parkinsons Dis. 8:171. PubMed
  5. Kerns JS, et al. 2023. Bio Protoc. 13: . PubMed
  6. Leick MB, et al. 2022. Cancer Cell. 40:494. PubMed
  7. Søgaard O, et al. 2015. PLoS One. 11: 1005142. PubMed
  8. Couturier J, et al. 2016. Retroviology. 13:30. PubMed
  9. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  10. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  11. Felce SL, et al. 2021. Wellcome Open Res. 5:42. PubMed
  12. Anderson W, et al. 2023. Elife. 12:. PubMed
  13. Pinto C, et al. 2023. iScience. 26:106381. PubMed
  14. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  15. Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed
  16. Netsrithong R, et al. 2020. Stem Cell Research. 39:101487.. PubMed
  17. Manukyan G, et al. 2020. Auto Immun Highlights. 11:5. PubMed
  18. Zeng W, et al. 2017. Front Immunol. 0.806944444. PubMed
  19. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  20. Wu Y, et al. 2021. Nat Biomed Eng. 5:1336. PubMed
  21. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  22. Gao Y, et al. 2021. Oncogenesis. 10:62. PubMed
  23. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  24. Bonnefoy F, et al. 2018. Front Immunol. 2.170833333. PubMed
  25. Seamon K, et al. 2020. Front Immunol. 11:396. PubMed
  26. Huang C, et al. 2020. Theranostics. 10:10498. PubMed
  27. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  28. Urbanska K, et al. 2015. Cancer Immunol Res. 3: 1130 - 1137. PubMed
  29. Paraiso HC, et al. 2018. J Neuroinflammation. 0.694444444. PubMed
  30. Turner AW, et al. 2020. ACS Infect Dis. 6:1719. PubMed
  31. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  32. Huang M, et al. 2021. BMC Infect Dis. 21:922. PubMed
  33. Hill ZB, et al. 2018. Nat Chem Biol. 14:112. PubMed
  34. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  35. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  36. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  37. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  38. Zhang J, et al. 2022. Nature. 609:369. PubMed
  39. Luengo A, et al. 2020. Molecular Cell. 81(4):691-707.e6. PubMed
  40. Arcangeli S, et al. 2022. J Clin Invest. 132: . PubMed
  41. Cai J, et al. 2021. eLife. 10:00. PubMed
  42. Liu Y, et al. 2022. Biochem J. 479:385. PubMed
  43. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  44. Draganov DD, et al. 2019. J Transl Med. 17:100. PubMed
  45. Jeng MY, et al. 2018. J Exp Med. 215:51. PubMed
  46. Cho JH, et al. 2021. Nat Commun. 12:792. PubMed
  47. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  48. Pan Y, et al. 2018. Proc Natl Acad Sci U S A. 115:992. PubMed
  49. Vinogradova EV, et al. 2020. Cell. 182(4):1009-1026.e29. PubMed
  50. Roybal KT et al. 2016. Cell. 167(2):419-432 . PubMed
  51. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  52. Georg P, et al. 2022. Cell. 185:493. PubMed
  53. Huang Z, et al. 2020. Sci Adv. 6:eaay9209. PubMed
  54. Fiorillo E, et al. 2010. J Biol Chem. 285:26506. PubMed
  55. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
  56. Wang Y, et al. 2021. Sci Adv. 7: . PubMed
  57. Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed
  58. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  59. Masuda N, et al. 2021. BMC Cancer. 21:1269. PubMed
  60. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  61. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  62. Lee YG, et al. 2019. Nat Commun. 10:2681. PubMed
  63. Li H, et al. 2020. Front Oncol. 1.477083333. PubMed
  64. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  65. Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed
  66. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  67. Warthan MD, et al. 2018. Biol Reprod. 98:309. PubMed
  68. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  69. Tiwarekar V, et al. 2018. J Virol. 92:17. PubMed
  70. Ickrath P, et al. 2018. Int J Mol Med. 42:1116. PubMed
  71. Schmidts A, et al. 2020. J Immunother Cancer. 8:. PubMed
  72. Dijkman K, et al. 2021. Cell Reports Medicine. 2(1):100187. PubMed
  73. van Galen P, et al. 2019. Cell. 176:1265. PubMed
RRID
AB_314844 (BioLegend Cat. No. 310909)
AB_314844 (BioLegend Cat. No. 310910)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD69 FN50 FC,CyTOF®,IHC-F
FITC anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
PE/Cyanine5 anti-human CD69 FN50 FC
APC anti-human CD69 FN50 FC
APC/Cyanine7 anti-human CD69 FN50 FC
PE/Cyanine7 anti-human CD69 FN50 FC
Alexa Fluor® 488 anti-human CD69 FN50 FC
Alexa Fluor® 647 anti-human CD69 FN50 FC,SB
Pacific Blue™ anti-human CD69 FN50 FC
Alexa Fluor® 700 anti-human CD69 FN50 FC
Biotin anti-human CD69 FN50 FC
PerCP/Cyanine5.5 anti-human CD69 FN50 FC
PerCP anti-human CD69 FN50 FC
Brilliant Violet 421™ anti-human CD69 FN50 FC
Brilliant Violet 785™ anti-human CD69 FN50 FC
Brilliant Violet 650™ anti-human CD69 FN50 FC
Brilliant Violet 510™ anti-human CD69 FN50 FC
Brilliant Violet 605™ anti-human CD69 FN50 FC
Purified anti-human CD69 (Maxpar® Ready) FN50 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD69 FN50 FC
Brilliant Violet 711™ anti-human CD69 FN50 FC
APC/Fire™ 750 anti-human CD69 FN50 FC
TotalSeq™-A0146 anti-human CD69 FN50 PG
TotalSeq™-B0146 anti-human CD69 FN50 PG
TotalSeq™-C0146 anti-human CD69 FN50 PG
Brilliant Violet 750™ anti-human CD69 FN50 FC
KIRAVIA Blue 520™ anti-human CD69 FN50 FC
Spark NIR™ 685 anti-human CD69 Antibody FN50 FC
PE/Fire™ 640 anti-human CD69 FN50 FC
Spark YG™ 581 anti-human CD69 FN50 FC
TotalSeq™-D0146 anti-human CD69 FN50 PG
APC anti-human CD69 FN50 FC
Spark Blue™ 550 anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
Spark Red™ 718 anti-human CD69 FN50 FC
GMP PE anti-human CD69 FN50 FC
PE/Fire™ 810 anti-human CD69 FN50 FC
PE/Fire™ 744 anti-human CD69 FN50 FC
Spark PLUS UV395™ anti-human CD69 FN50 FC
Spark Blue™ 574 anti-human CD69 (Flexi-Fluor™) FN50 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account